{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:34:05Z","timestamp":1792600445331,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,12,14]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg\/kg\/day prednisone equivalent with or without a preceding intravenous methylprednisolone pulse. More recent management guidelines recommend lower starting oral GC doses following intravenous pulse therapy. As there have been no large studies directly comparing patients receiving low versus high initial oral GC doses, this pooled analysis of high-quality randomised controlled trials (RCTs) aims to evaluate differences in efficacy and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Published data were analysed from RCTs that assessed variable GC doses in the standard of care (SOC) treatment arms. Patients receiving starting prednisone doses up to 0.5 mg\/kg\/day (low dose) were compared with 1.0 mg\/kg\/day (high dose). Complete renal response requiring urine protein-creatinine ratio &lt;0.5\u2009mg\/mg (CRR 0.5), CRR or partial renal response (PRR), serious adverse events (SAE) and SAE due to infections at 12 months of treatment were compared between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>417 patients from SOC arms of five studies were exposed to low-dose initial GC after intravenous pulse, while 521 patients from four studies were treated with high-dose oral GC. In patients with low-dose oral GC, 25.2% achieved CRR 0.5 at 12 months compared with 27.2% in high-dose groups, p=0.54. CRR or PRR was attained in 48.7% low-dose vs 43.6% high-dose patients, p=0.14. SAEs and infection SAEs were less common in the low-dose GC group (19.4% vs 31.6%, p&lt;0.001\u2009and 9.8% vs 16.5%, p=0.012, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Based on pooled RCT data, there was no significant difference in 12-month renal responses between patients receiving low-dose prednisone following intravenous GC compared with those receiving initial high doses. SAEs were less frequent in patients receiving low-dose initial GC. These findings support the use of lower oral GC doses in LN treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001351","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:00:22Z","timestamp":1736197222000},"page":"e001351","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-1083","authenticated-orcid":false,"given":"Amit","family":"Saxena","sequence":"first","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sorrento","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Izmirly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gamez-Perez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jammie","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Michael","family":"Belmont","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-7129","authenticated-orcid":false,"given":"Jill P","family":"Buyon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2025091514283743000_12.1.e001351.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39026"},{"key":"2025091514283743000_12.1.e001351.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664"},{"key":"2025091514283743000_12.1.e001351.3","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30105-5"},{"key":"2025091514283743000_12.1.e001351.4","first-page":"1484","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus (Los Angel)"},{"key":"2025091514283743000_12.1.e001351.5","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14265"},{"key":"2025091514283743000_12.1.e001351.6","doi-asserted-by":"publisher","DOI":"10.4103\/ijn.IJN_299_18"},{"key":"2025091514283743000_12.1.e001351.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3936"},{"key":"2025091514283743000_12.1.e001351.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"2025091514283743000_12.1.e001351.9","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","volume":"6","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025091514283743000_12.1.e001351.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41014"},{"key":"2025091514283743000_12.1.e001351.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920"},{"key":"2025091514283743000_12.1.e001351.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.025"},{"key":"2025091514283743000_12.1.e001351.13","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"The Lancet"},{"key":"2025091514283743000_12.1.e001351.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"2025091514283743000_12.1.e001351.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2025091514283743000_12.1.e001351.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.38037"},{"key":"2025091514283743000_12.1.e001351.17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091514283743000_12.1.e001351.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2025091514283743000_12.1.e001351.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.42557"},{"key":"2025091514283743000_12.1.e001351.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.42920"},{"key":"2025091514283743000_12.1.e001351.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120537"},{"key":"2025091514283743000_12.1.e001351.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.013"},{"key":"2025091514283743000_12.1.e001351.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.05.017"},{"key":"2025091514283743000_12.1.e001351.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102898"},{"key":"2025091514283743000_12.1.e001351.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03275-z","article-title":"Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network","volume":"26","author":"Izmirly","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2025091514283743000_12.1.e001351.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24592"},{"key":"2025091514283743000_12.1.e001351.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa403"},{"key":"2025091514283743000_12.1.e001351.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.003574"},{"key":"2025091514283743000_12.1.e001351.29","unstructured":"Saxena A , Izmirly P , Law J , et al . High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials. Arthritis Rheumatol 2023;75."}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:28:48Z","timestamp":1757971728000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/lupus-2024-001351"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001351","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}